

## Elevated levels of mutation in multiple tissues of mice deficient in the DNA mismatch repair gene *Pms2*

(transgenic mice/supF/genetic instability/cancer)

LATHA NARAYANAN\*, JAMES A. FRITZELL\*, SEAN M. BAKER†, R. MICHAEL LISKAY†, AND PETER M. GLAZER\*‡

\*Departments of Therapeutic Radiology and Genetics, Yale University School of Medicine, Post Office Box 208040, New Haven, CT 06520-8040; and  
†Department of Molecular and Medical Genetics, Oregon Health Sciences University, Portland, OR 97201-3098

Communicated by Richard B. Setlow, Brookhaven National Laboratory, Upton, NY, January 16, 1997 (received for review October 24, 1996)

**ABSTRACT** The *Pms2* gene has been implicated in hereditary colon cancer and is one of several mammalian homologs of the *Escherichia coli* *mutL* DNA mismatch repair gene. To determine the effect of *Pms2* inactivation on genomic integrity *in vivo*, hybrid transgenic mice were constructed that carry targeted disruptions at the *Pms2* loci along with a chromosomally integrated mutation reporter gene. In the absence of any mutagenic treatment, mice nullizygous for *Pms2* showed a 100-fold elevation in mutation frequency in all tissues examined compared with both wild-type and heterozygous litter mates. The mutation pattern in the nullizygotes was notable for frequent 1-bp deletions and insertions within mononucleotide repeat sequences, consistent with an essential role for PMS2 in the repair of replication slippage errors. Further, the results demonstrate that high rates of mutagenesis in multiple tissues are compatible with normal development and life and are not necessarily associated with accelerated aging. Also, the finding of genetic instability in all tissues tested contrasts with the limited tissue distribution of cancers in the animals, raising important questions regarding the role of mutagenesis in carcinogenesis.

Hereditary nonpolyposis colorectal cancer (HNPCC) has been linked to germ-line mutations in the human homologs of *Escherichia coli* and yeast DNA mismatch repair genes (1–3). Recent work has revealed that mammalian cells contain multiple homologs of the *E. coli* MutS and MutL proteins, including MSH2, MSH3/DUG1/MRP1, and GTBP/MSH6 (1, 2, 4–6) and MLH1, PMS2, and PMS1 (1, 2, 7–9), respectively. Biochemical studies with mammalian or yeast cell extracts or partially purified proteins have shown that the MutS homologs can associate in heterodimers in at least two combinations (MSH2 with MSH3 and MSH2 with GTBP/MSH6), each with different activities and mismatch substrate specificities, suggesting both redundancy and divergence of function (1, 10, 11). Studies with the MutL homologs suggest that MLH1 and PMS2 form a functional heterodimer (12–14); other possible MutL complexes have yet to be characterized.

In addition, evidence is emerging that the mismatch repair gene homologs may participate in various other cellular functions, such as transcription-coupled repair (15), recombination (16), and even cell cycle regulation (17). Consequently, a deficiency in one of these homologs may disrupt genome stability in multiple ways.

Previous attempts to evaluate the specific *in vivo* role of each of the mammalian mismatch repair homologs have been based for the most part on comparisons of changes at microsatellite

loci. However, these assays report only expansion or contraction of simple repeated sequences, representing just one specific subset of all possible genetic changes. Forward mutation assays, in contrast, are capable of detecting a wide range of mutations. Such assays have been carried out with the selectable *HPRT* locus in colon cancer-derived cell lines, some of which are deficient in DNA mismatch repair. These studies have revealed some significant differences among the mutation patterns in different lines (18, 19). However, such tumor cell lines are likely to contain multiple genetic abnormalities besides mismatch repair gene defects, and some of these might affect DNA metabolism, complicating interpretation of the experiments.

Hence, the full impact of *Pms2* inactivation on genomic integrity *in vivo* has not yet been elucidated. Herein we report the construction and analysis of hybrid transgenic mice carrying targeted disruptions at the *Pms2* loci along with a chromosomally integrated mutation reporter gene contained within a recoverable  $\lambda$  phage shuttle vector. Data are presented showing that mice nullizygous for *Pms2* have high levels of spontaneous mutagenesis in multiple tissues, even those not associated with an increased risk of cancer. In addition, *Pms2* inactivation is shown to predispose to deletions and insertions, with a significantly lesser impact on the occurrence of base substitutions.

### MATERIALS AND METHODS

**Transgenic Mice.** Construction of the *Pms2*-deficient mice (using D3 embryonic stem cells of 129/Sv mouse origin) has been described (20). The 3340 *supFG1* mice were produced as described for the 1139 mice (21) except that the *supFG1* gene was substituted for *supF* in the  $\lambda$  vector. Both were derived from the C57BL/6 mouse background. Construction of the *supFG1* gene has been described (22). The *Pms2* genotype of the mice was determined by the presence or absence of the targeted insertion by PCR amplification of a region in the *Pms2* gene as described (20). The presence of the *supFG1* or *supF* gene in the mice was also confirmed by PCR amplification, as described (21).

**$\lambda$  Shuttle Vector Rescue and Analysis.** High molecular weight DNA was prepared from selected mouse tissues as described (21).  $\lambda$  vector rescue from the mouse DNA was carried out with  $\lambda$  *in vitro* packaging extracts (21, 23, 24). Packaging extracts were made as described (23), except that a new *E. coli* lysogen, NM759 [*E. coli* K12 *recA56*  $\Delta$ (*mcrA*) *e14* $\Delta$ (*mrr-hsd-mcr*) (*imm434* *clts* *b2* *red3* *Dam15* *Sam7*)/ $\lambda$ ] was used instead of BHB2690 for the preparation of the sonicate extract (24). This lysogen produces extracts that are deficient in methyl-directed restriction activity that would otherwise degrade DNA methylated in the mammalian

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Copyright © 1997 by THE NATIONAL ACADEMY OF SCIENCES OF THE USA  
0027-8424/97/943122-6\$2.00/0  
PNAS is available online at <http://www.pnas.org>.

Abbreviation: HNPCC, hereditary nonpolyposis colorectal cancer.  
‡To whom reprint requests should be addressed. e-mail: peter.glazer@qm.yale.edu.

pattern and reduce the yield of rescued phage (24, 25). The mouse DNA was incubated in the  $\lambda$  *in vitro* packaging extracts at a concentration of 0.05  $\mu\text{g}/\mu\text{l}$  for 2 h at 37°C. The packaged phage were diluted in 10 mM Tris-HCl, pH 8.0/5 mM  $\text{MgCl}_2$ , adsorbed to PG901 [*E. coli* C1a *lacZ*125 (*am*)], and plated in 0.6% top agar on LB plates in the presence of 5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactoside (1.6 mg/ml) and isopropyl  $\beta$ -D-thiogalactoside (1.3 mg/ml), as described (23). Phage with functional *supF* genes suppress the nonsense mutation in the host bacteria  $\beta$ -galactosidase gene, allowing synthesis of active enzyme capable of metabolizing 5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactoside, thereby yielding blue plaques. Phage with inactivating *supF* mutations produce colorless plaques.

**Mutation Sequencing.** After plaque purification, PCR amplification of the *supF* gene sequences was carried out with the GeneAmp kit (Perkin-Elmer/Cetus). Sequence analysis of the PCR products was performed as described (26).

## RESULTS

**Construction of Hybrid Transgenic Mice.** To elucidate in a well-defined system the *in vivo* role of the MutL homologs, mice deficient for *Pms2* were constructed by gene targeting in embryonic stem cells (20). Initial studies of the *Pms2* nullizygotes revealed increased microsatellite mutation, sterility in males, and the development of lymphomas and sarcomas within the first year of age (20). To study genetic instability in multiple tissues from these mice, we designed an *in vivo* forward mutation assay. The *Pms2*-deficient mice were bred with transgenic mice carrying the *supF* tRNA suppressor gene as a mutation reporter gene within a chromosomally integrated recoverable  $\lambda$  phage shuttle vector (21, 23). By using  $\lambda$  *in vitro* packaging extracts, the vector DNA can be identified, excised, and packaged from within the mouse DNA into viable  $\lambda$  particles for analysis in bacteria of *supF* mutations that occurred in the animals (23, 24). These *supF* mice therefore provide an *in vivo* mutation reporter system that can detect base substitutions, as well as deletions and insertions. Consequently, this system for reporting mutations is more sensitive and complete than the standard PCR-based assay of microsatellite stability.

To enhance the sensitivity of the assay even further, we used two independent lines of *supF* mice, one (1139) carrying the standard *supF* gene (21) and another (3340) with a *supF* gene modified to contain extended simple sequence repeats (*supFG1*) (22). Male *supF*-positive mice were bred with *Pms2* heterozygous females to construct hybrid transgenic mice. The  $F_1$  mice were crossed to produce  $F_2$  mice that were wild type, heterozygous, or nullizygous at the *Pms2* loci and that also carried the *supF* transgene.

**Analysis of Spontaneous Mutagenesis *in Vivo*.** Three independent sets of 3340/*Pms2* male litter mates were identified for analysis at 12 weeks of age. The mice were maintained under standard animal husbandry conditions in the same cage. There was no known exposure to any mutagenic or genotoxic agent. DNA was prepared from several different tissues of the mice and used for vector rescue (via *in vitro* packaging) and reporter gene analysis (Table 1).

The frequency of mutations in the wild-type mice was in the range of 1 to 2  $\times 10^{-5}$ , consistent with previous observations of baseline mutation frequencies in such transgenic animal systems (21, 25, 27). However, the nullizygote samples consistently showed 100-fold or more elevations in mutation frequencies in all tissues and mice tested (Table 1). Significant tissue to tissue differences were not detected, with the largest difference being 2-fold (between liver and colon in F2-19). However, colon in F2-29 showed a slightly lower frequency than in F2-19, and there were similar slight fluctuations in the data from the skin samples from the three nullizygous mice. Analysis of the heterozygotes revealed

Table 1. Spontaneous mutagenesis of the *supFG1* transgene in *Pms2*-deficient 3340 mice

Mouse/tissue	Mutation frequency ( $\times 10^{-5}$ )	No. mutants/ total no.
Wild type		
Mouse F2-17		
Skin	$\leq 2$	0/72,990
Liver	4	6/170,260
Mouse F3-9		
Skin	$\leq 2$	0/72,240
Colon	2	1/45,620
Total	2	7/361,110
Heterozygous		
Mouse F2-18		
Skin	5	5/92,730
Liver	4	5/131,500
Spleen	$\leq 2$	0/75,630
Colon	$\leq 2$	0/78,620
Mouse F2-4		
Skin	1	1/87,690
Mouse F3-13		
Skin	2	1/51,600
Total	2	12/517,760
Nullizygous		
Mouse F2-19		
Skin	237	302/127,700
Liver	132	55/41,700
Spleen	226	33/14,620
Colon	286	201/70,360
Brain	270	53/19,610
Lung	206	35/16,980
Mouse F2-29		
Skin	177	27/15,270
Spleen	182	27/14,850
Colon	187	37/19,780
Mouse F3-11		
Skin	173	58/33,590
Liver	118	54/45,650
Total	210	882/420,110

mutation frequencies similar to those found in the wild-type animals.

In the 1139/*Pms2* hybrids, the nullizygotes showed only a 5-fold overall increase in mutation frequency (Table 2). However, the 1139 mice were previously found to have an unusually high frequency of spontaneous deletions due to locus-specific effects at the transgene integration site (21). When only *supF* point mutations are considered, the nullizygotes again show a substantial elevation in mutation frequency of approximately 25-fold relative to the wild-type mice (Table 2).


**Mutation Patterns.** The mutations arising in the nullizygous mice were analyzed at the sequence level (Fig. 1 and Table 3). Almost all of the mutations in the 3340/*Pms2* nullizygotes (71 out of 74) were single-base pair deletions or insertions within the G-C base pair repeats at positions 99–105 and 172–179. The eight G-C base pair run at positions 172–179 is a particular hot spot. Note that this stretch constitutes a subset of a longer G-C-rich region that extends beyond the end of the tRNA gene at position 183. This pattern was seen in multiple tissues in three different nullizygous mice from three different litters (Fig. 14).

In the 1139 mice, single-base pair insertions and deletions were less prominent (6 of 18 mutations) but were still more frequent than in the wild-type mice (0 of 30 mutations) (Fig. 1B and Table 3). The difference in mutation pattern between the 3340 and the 1139 mice can be attributed in part to the differences in the reporter genes. *SupFG1* in 3340 mice has two runs of 7 and 8 G-C base pairs, respectively. The longest


A.

3340/*PMS2* nullizygotes


Mouse F2-19 (skin, liver, and colon)




Mouse F2-29 (skin, liver, colon)



Mouse F3-11 (skin)



B.

1139/*PMS2* nullizygotes

## 1139 wild type




FIG. 1. Sequences of reporter gene mutations in *Pms2* nullizygous mice. (A) Mutations in the *supFG1* gene in 3340/*Pms2* nullizygotes. Mutations from three different mice from independent litters are shown, with the tissues of origin indicated. Base substitutions are listed above the original sequence, and single-base pair deletions or insertions are indicated by  $\Delta$  or +, respectively, above the corresponding site. Mononucleotide repeat sequences are highlighted by double underlining. CpG sequences, potential sites of cytosine methylation, are noted by a single underline. (B) Mutations in the *supF* gene in 1139/*Pms2* nullizygotes and in wild-type 1139 mice, as indicated.

repeat sequence in the *supF* gene in the 1139 mice, however, is a 5 G-C base pair stretch at positions 171–176. We propose that this shorter region is less susceptible to slippage replication errors (28) and is, therefore, less dependent on *Pms2* function for stability.

The base substitutions in the nullizygotes were mostly transitions (Table 3). Because there were so few base substitutions in the 3340/*Pms2* nullizygotes (only 3 of 74

mutations), the main comparison to be made is between the 1139/*Pms2* nullizygotes and the wild-type mice. Overall, the spectra of base substitutions are similar except that the proportion of C  $\rightarrow$  T transitions at CpG sites in the nullizygotes is only 11%, compared with 47% in the wild type. Because CpG sites are subject to cytosine methylation in mammalian cells, transitions at these positions are thought to arise from the propensity of 5-methylcytosine to deaminate

Table 2. Spontaneous mutagenesis of the *supF* transgene in *Pms2*-deficient 1139 mice

Mouse/tissue	Mutation frequency ( $\times 10^{-5}$ )	No. mutants/total no.	% point mutations	% deletions	Frequency of point mutations ( $\times 10^{-5}$ )
Wild type					
Skin	39	199/511,950			
Liver	29	47/199,010			
Spleen	35	82/232,580			
Total	35	328/943,540	6	94	2
Nullizygous					
Skin	117	163/138,910			
Liver	139	165/118,860			
Spleen	154	151/98,360			
Total	135	479/356,120	42	58	57

to thymidine. Although such mutations do occur in the *Pms2* nullizygotes, they are under-represented relative to those in the wild-type animals, suggesting that *Pms2* is not essential for repair of these lesions. This is consistent with reports of an alternate repair pathway involving a glycosylase specific for the G-U and G-T mismatches that are produced by deamination (29, 30). The paucity of methylcytosine-related transitions in the nullizygotes is not due to undermethylation of the transgene sequences. The *supF* transgenes in both the 3340 and 1139 mice are each heavily methylated, as determined by comparison of susceptibility of the mouse genomic DNA to *HpaII* and *MspI* digestion (data not shown).

## DISCUSSION

We have detected high somatic mutation frequencies in *Pms2* nullizygous mice of up to 100-fold above the wild-type background. Mice heterozygous for the *Pms2* disruption did not show increased spontaneous mutagenesis, suggesting that a single functional allele provides near normal repair activity and that *Pms2*-related genetic instability may, therefore, be recessive. However, we cannot rule out the possibility that the heterozygotes do have a low level of genetic instability, since slight increases in mutation frequency (such as 2-fold or less) are difficult to reliably detect in this assay, even with the analysis of large numbers of animals and phage. In light of the apparent participation of mismatch repair factors in aspects of DNA repair other than mismatch correction (15, 31), differences between the heterozygotes and the wild-type mice may eventually be revealed by studies of induced mutagenesis.

The heterozygous mice mimic the situation in most patients with the HNPCC syndrome, who are also heterozygous at one of the mismatch repair loci in their somatic cells (1, 3). Their tumors, however, are characterized by loss or inactivation of the second allele, leading to genomic instability. Such loss of heterozygosity events should also be possible in mice, thus

predisposing the affected cell lineages to *supF* mutations. However, the low mutation frequencies in the heterozygotes suggest that such events are rare.

The spectrum of mutations in the nullizygotes is consistent with a primary role for *Pms2* in the correction of slippage errors occurring during replication of repeated sequences (28). By comparison of the results in the *supF* and *supFGL* reporter genes, we can conclude that seven or more mononucleotides are particularly unstable *in vivo*. This is consistent with the frequent finding of frameshift mutations within a 10 A-T base-pair run in the transforming growth factor  $\beta$  receptor gene in a series of colon cancer cell lines (32, 33). Such long mononucleotide runs are also particularly common within promoters and introns. For example, the *c-myc* promoter contains several extended runs of G-C base pairs (34), and the binding site for the Sp1 transcription factor is highly G+C-rich (35). We would predict that these regulatory regions would be especially unstable in the setting of *Pms2* deficiency, leading to accumulating abnormalities in gene expression and thereby contributing to aberrant cellular function and eventually carcinogenesis.

The reduced frequency of C  $\rightarrow$  T transitions at CpG sites in the *Pms2* nullizygotes is in contrast to the results of Andrew and colleagues (S. E. Andrew, A. H. Reitmar, J. Fox, L. Hsiao, A. Francis, M. McKinnon, T. W. Mak, and F. Jirik, personal communication), who have found a higher frequency of such mutations in mice deficient in the MutS homolog *Msh2*. Since they used a different mutation reporter gene (*lacI*), the discrepancy could be attributed to the known propensity for such mutations in the *lacI* transgene (27). Also, the different loci of integration of the reporter genes may influence the mutation pattern, as has occasionally been seen in transgenic constructs (21, 36). It is also possible, however, that *Msh2* has a role in the repair of the G-T mismatches that result from deamination of methylcytosine.

In addition, the mutation frequency in the *Msh2*-deficient mice studied by Andrew *et al.* (personal communication) is somewhat less than that seen in the *Pms2* nullizygotes. Some of this difference may again be explained by differences in the reporter genes. Nonetheless, the comparison indicates that *Pms2* deficiency results in a degree of genetic instability at least as severe as that caused by lack of *Msh2*. Hence, the observation that *Msh2* mutations are more common in HNPCC patients than are *Pms2* mutations (2, 8) cannot be attributed to a greater impact of *Msh2* mutations on genetic instability. Possibly, it could relate to differences in the mutation spectra, although these differences need to be confirmed in other target genes. More likely, *Msh2* mutations may be more prevalent because of other factors, such as an increased susceptibility of the *Msh2* locus itself to mutation or to loss of heterozygosity.

The nullizygous mice showed increased mutation in all tissues tested, including skin, liver, spleen, colon, brain, and lung. However, these animals appear to be predisposed to

Table 3. Mutations in *Pms2* nullizygous mice

Mutation	3340/PMS2 nullizygotes, no.	1139/PMS2 nullizygotes, no.	1139 wild-type mice, no.
C-G $\rightarrow$ T-A	1	5	23
T-A $\rightarrow$ C-G	1	3	2
C-G $\rightarrow$ A-T	0	1	3
C-G $\rightarrow$ G-C	1	0	1
T-A $\rightarrow$ A-T	0	2	0
T-A $\rightarrow$ G-C	0	1	1
C-G $\rightarrow$ T-A at CpG	1	2	14
+1 insertion	24	4	0
-1 deletion	47	2	0
Total	74	18	30

only lymphomas and sarcomas (20). This disparity shows that mutagenesis is just one element in carcinogenesis, highlighting the complexity of cancer etiology. Additional factors could include tissue damage and aberrant mitogenic stimuli. However, the particular factors that influence the tissue distribution of neoplasms in the mice remain to be determined. In HNPCC patients, the range of tumors is also limited; but it is different from that seen in the mice, with epithelial cancers of the colon most common. One explanation for this difference could be that most of the HNPCC patients are genotypically heterozygotes, and inactivation of the second mismatch repair gene allele is a critical step in the progression to neoplasm (1, 3, 37). Tissue-specific factors that vary among species, such as differential exposure to diet-derived genotoxic agents in the colon, may play an important part in promoting the loss of heterozygosity.

Several unusual patients, however, have been found to lack mismatch repair activity in their nonneoplastic tissues and in their cancers (38, 39). Two of these were determined to be heterozygous at the *Pms2* locus, but in each case the mutant allele was found to code for a truncated protein with apparent dominant negative activity. In terms of *Pms2*-related mismatch repair function, the phenotype of these patients is, therefore, similar to that of the *Pms2*-nullizygous mice; yet, they developed colorectal carcinomas, not lymphomas or sarcomas. This difference suggests that there may be additional species-specific factors influencing tumor distribution. Determining whether these factors are genetic in nature (such as differences in the controls on growth and differentiation) or reflect environmental and life style differences will require further study.

Nonetheless, the *Pms2* nullizygous mice described here show, remarkably, that high levels of spontaneous somatic mutations are compatible with mostly normal development and life, except for early onset carcinogenesis and male infertility (20). It might be predicted that such profound genetic instability would also cause accelerated aging, but this has not yet been demonstrated in the mice. Recently, Werner syndrome, a disease of premature aging and predisposition to malignancy, has been linked to a gene encoding a putative DNA helicase (40). In this disorder, the lack of helicase activity is hypothesized to lead to the accumulation of genetic abnormalities, producing early cellular senescence. However, mutations in Werner cells include a high proportion of large deletions (41), rather than point mutations as seen in the *Pms2* mice. Whether this difference in mutation pattern accounts for the differences in carcinogenesis and aging remains to be determined.

We thank E. G. Leach, T. Y. Reynolds, E. G. Gunther, G. Wang, R. Franklin, S. J. Baserga, and L. Cabral for their help; and we thank S. Andrew and F. Jirik for sharing their results with *Msh2*-deficient mice. This work was supported by the Charles E. Culpeper Foundation, the Leukemia Society of America, and the National Institutes of Health (Grant ES05775).

- Kolodner, R. (1996) *Genes Dev.* **10**, 1433–1442.
- Modrich, P. & Lahue, R. (1996) *Annu. Rev. Biochem.* **65**, 101–133.
- de la Chapelle, A. & Peltomäki, P. (1995) *Annu. Rev. Genet.* **29**, 329–348.
- Fishel, R., Lescoe, M. K., Rao, M. R., Copeland, N. G., Jenkins, N. A., Garber, J., Kane, M. & Kolodner, R. (1993) *Cell* **75**, 1027–1038.
- Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., *et al.* (1993) *Cell* **75**, 1215–1225.
- Papadopoulos, N., Nicolaides, N. C., Liu, B., Parsons, R., Lengauer, C., Palombo, F., D'Arrigo, A., Markowitz, S., Willson, J. K., Kinzler, K. W., Jiricny, J. & Vogelstein, B. (1995) *Science* **268**, 1915–1917.
- Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R. J., Godwin, A. R., Ward, D. C., Nordenskjöld, M., Fishel, R., Kolodner, R. & Liskay, R. M. (1994) *Nature (London)* **368**, 258–261.
- Nicolaides, N. C., Papadopoulos, N., Liu, B., Wei, Y. F., Carter, K. C., Ruben, S. M., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., Venter, J. C., Dunlop, M. G., Hamilton, S. R., Petersen, G. M., de la Chapelle, A., Vogelstein, B. & Kinzler, K. W. (1994) *Nature (London)* **371**, 75–80.
- Papadopoulos, N., Nicolaides, N. C., Wei, Y. F., Ruben, S. M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., Venter, J. C., Hamilton, S. R., Petersen, G. M., Watson, P., Lynch, H. T., Peltomäki, P., Mecklin, J., de la Chapelle, A., Kinzler, K. V. & Vogelstein, B. (1994) *Science* **263**, 1625–1629.
- Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M., D'Arrigo, A., Truong, O., Hsuan, J. J. & Jiricny, J. (1995) *Science* **268**, 1912–1914.
- Drummond, J. T., Li, G. M., Longley, M. J. & Modrich, P. (1995) *Science* **268**, 1909–1912.
- Prolla, T. A., Pang, Q., Alani, E., Kolodner, R. D. & Liskay, R. M. (1994) *Science* **265**, 1091–1093.
- Prolla, T. A., Christie, D. M. & Liskay, R. M. (1994) *Mol. Cell. Biol.* **14**, 407–415.
- Li, G. M. & Modrich, P. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 1950–1954.
- Mellon, I., Rajpal, D. K., Koi, M., Boland, C. R. & Champe, G. N. (1996) *Science* **272**, 557–560.
- Worth, L. Jr., Clark, S., Radman, M. & Modrich, P. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 3238–3241.
- Hawn, M. T., Umar, A., Carethers, J. M., Marra, G., Kunkel, T. A., Boland, C. R. & Koi, M. (1995) *Cancer Res.* **55**, 3721–3725.
- Bhattacharyya, N. P., Skandalis, A., Ganesh, A., Groden, J. & Meuth, M. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 6319–6323.
- Eshleman, J. R., Lang, E. Z., Bowerfind, G. K., Parsons, R., Vogelstein, B., Willson, J. K. V., Veigl, M. L., Sedwick, W. D. & Markowitz, S. D. (1995) *Oncogene* **10**, 33–37.
- Baker, S. M., Bronner, C. E., Zhang, L., Plug, A. W., Robatzek, M., Warren, G., Elliott, E. A., Yu, J., Ashley, T., Arnheim, N., Flavell, R. A. & Liskay, R. M. (1995) *Cell* **82**, 309–319.
- Leach, E. G., Gunther, E. J., Yeasky, T. M., Gibson, L. H., Yang-Feng, T. L. & Glazer, P. M. (1996) *Mutagenesis* **11**, 49–56.
- Wang, G., Levy, D. D., Seidman, M. M. & Glazer, P. M. (1995) *Mol. Cell. Biol.* **15**, 1759–1768.
- Glazer, P. M., Sarkar, S. N. & Summers, W. C. (1986) *Proc. Natl. Acad. Sci. USA* **83**, 1041–1044.
- Gunther, E. J., Murray, N. E. & Glazer, P. M. (1993) *Nucleic Acids Res.* **21**, 3903–3904.
- Gossen, J. A., de Leeuw, W. J., Tan, C. H., Zwarthoff, E. C., Berends, F., Lohman, P. H., Knook, D. L. & Vijg, J. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 7971–7975.
- Havre, P. A., Gunther, E. J., Gasparro, F. P. & Glazer, P. M. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 7879–7883.
- Kohler, S. W., Provost, G. S., Fieck, A., Kretz, P. L., Bullock, W. O., Sorge, J. A., Putman, D. L. & Short, J. M. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 7958–7962.
- Streisinger, G., Okada, Y., Emrich, J., Newton, J., Tsugita, A., Terzah, E. & Inoye, M. (1966) *Cold Spring Harbor Symp. Quant. Biol.* **31**, 77–84.
- Wiebauer, K. & Jiricny, J. (1990) *Proc. Natl. Acad. Sci. USA* **87**, 5842–5845.
- Neddermann, P. & Jiricny, J. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 1642–1646.
- Branch, P., Aquilina, G., Bignami, M. & Karran, P. (1993) *Nature (London)* **362**, 652–654.
- Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L. Z., Lutterbaugh, J., Fan, R. S., Zborowska, E., Kinzler, K. W., Vogelstein, B., Brattain, M. & Willson, J. K. V. (1995) *Science* **268**, 1336–1338.
- Parsons, R., Myeroff, L. L., Liu, B., Willson, J. K., Markowitz, S. D., Kinzler, K. W. & Vogelstein, B. (1995) *Cancer Res.* **55**, 5548–5550.
- Postel, E. H., Flint, S. J., Kessler, D. J. & Hogan, M. E. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 8227–8231.
- Briggs, M. R., Kadonaga, J. T., Bell, S. P. & Tjian, R. (1986) *Science* **234**, 47–52.

36. Gossen, J. A., de Leeuw, W. J., Verwest, A., Lohman, P. H. & Vijg, J. (1991) *Mutat. Res.* **250**, 423–429.
37. Modrich, P. (1994) *Science* **266**, 1959–1960.
38. Parsons, R., Li, G. M., Longley, M., Modrich, P., Liu, B., Berk, T., Hamilton, S. R., Kinzler, K. W. & Vogelstein, B. (1995) *Science* **268**, 738–740.
39. Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., Krush, A. J., Wood, P. A., Taqi, F., Booker, S. V., Petersen, G. M., Offerhaus, G. J. A., Tersmette, A. C., Giardiello, F. M., Vogelstein, B. & Kinzler, K. W. (1995) *N. Engl. J. Med.* **332**, 839–847.
40. Yu, C., Oshima, J., Fu, Y., Wijsman, E. M., Hisama, F., Alisch, R., Matthews, S., Nakura, J., Miki, T., Ouais, S., Martin, G. M., Mulligan, J. & Schellenberg, G. D. (1996) *Science* **272**, 258–262.
41. Fukuchi, K., Martin, G. M. & Monnat, R. J., Jr. (1989) *Proc. Natl. Acad. Sci. USA* **86**, 5893–5897.